STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia.


Journal

Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585

Informations de publication

Date de publication:
23 04 2019
Historique:
received: 30 01 2019
accepted: 02 04 2019
entrez: 25 4 2019
pubmed: 25 4 2019
medline: 8 7 2020
Statut: epublish

Résumé

Dysregulation in calcium (Ca An extensive analysis of the Ca Seeking to explore the CE pathway, we found in untreated CLL patients that an abnormal CE pathway was (i) highly associated with the disease outcome; (ii) positively correlated with basal Ca These data establish the critical role of a newly discovered BCR independent Ca

Sections du résumé

BACKGROUND
Dysregulation in calcium (Ca
METHODS
An extensive analysis of the Ca
RESULTS
Seeking to explore the CE pathway, we found in untreated CLL patients that an abnormal CE pathway was (i) highly associated with the disease outcome; (ii) positively correlated with basal Ca
CONCLUSIONS
These data establish the critical role of a newly discovered BCR independent Ca

Identifiants

pubmed: 31014395
doi: 10.1186/s40425-019-0591-3
pii: 10.1186/s40425-019-0591-3
pmc: PMC6480884
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antineoplastic Agents, Immunological 0
Neoplasm Proteins 0
ORAI1 Protein 0
ORAI1 protein, human 0
RNA, Small Interfering 0
STIM1 protein, human 0
Stromal Interaction Molecule 1 0
TRPC Cation Channels 0
transient receptor potential cation channel, subfamily C, member 1 0
Calcium SY7Q814VUP

Banques de données

ClinicalTrials.gov
['NCT03294980']

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

111

Références

Cancer Res. 2013 Aug 1;73(15):4852-61
pubmed: 23774210
Am J Hematol. 2017 Sep;92(9):946-965
pubmed: 28782884
Cancer Res. 1997 Oct 15;57(20):4493-7
pubmed: 9377559
Oncogene. 2015 Sep 10;34(37):4808-20
pubmed: 25531324
Curr Top Microbiol Immunol. 2016;393:143-174
pubmed: 26369772
Biochim Biophys Acta. 2009 Oct;1793(10):1614-22
pubmed: 19631699
Nat Rev Immunol. 2007 Sep;7(9):690-702
pubmed: 17703229
J Chem Inf Model. 2017 Feb 27;57(2):335-344
pubmed: 28151650
Biochim Biophys Acta. 2000 Aug 31;1481(1):147-55
pubmed: 11004585
Biochim Biophys Acta. 2002 Apr 1;1596(1):131-7
pubmed: 11983428
Onco Targets Ther. 2016 Dec 19;10:31-34
pubmed: 28031720
Leukemia. 2015 Feb;29(2):321-8
pubmed: 24917358
PLoS Biol. 2011 Mar;9(3):e1001025
pubmed: 21408196
Int J Dev Biol. 2015;59(7-9):379-89
pubmed: 26679951
Nature. 2012 Sep 13;489(7415):309-12
pubmed: 22885698
Clin Epigenetics. 2017 Nov 28;9:122
pubmed: 29209431
Immunotherapy. 2016 May;8(5):569-81
pubmed: 27140410
Cell Calcium. 2007 Aug;42(2):183-91
pubmed: 17391754
J Immunol. 2011 Apr 15;186(8):4835-44
pubmed: 21398617
Oncotarget. 2018 Aug 3;9(60):31590-31605
pubmed: 30167081
Immunity. 2017 Oct 17;47(4):664-679.e6
pubmed: 29030115
Cell Mol Immunol. 2018 Feb;15(2):158-170
pubmed: 27499044
Nat Rev Dis Primers. 2017 Jan 19;3:16096
pubmed: 28102226
Blood. 2016 Aug 11;128(6):816-26
pubmed: 27301861
Immunol Rev. 2009 Sep;231(1):174-88
pubmed: 19754897
Mol Immunol. 2011 Sep;48(15-16):1851-8
pubmed: 21663969
Leukemia. 2015 Feb;29(2):356-68
pubmed: 24990614
Immunity. 2016 Jun 21;44(6):1350-64
pubmed: 27261277
J Immunol. 2005 Mar 15;174(6):3749-56
pubmed: 15749915
J Cell Biol. 1996 Aug;134(3):771-82
pubmed: 8707854
Cytogenet Cell Genet. 1999;86(3-4):214-8
pubmed: 10575208
Blood. 2012 Jul 12;120(2):356-65
pubmed: 22613791
Blood. 2011 Mar 10;117(10):2924-34
pubmed: 21193695
Clin Rev Allergy Immunol. 2017 Oct;53(2):141-165
pubmed: 28500564
J Physiol. 2007 Mar 15;579(Pt 3):703-15
pubmed: 17158173

Auteurs

Marjolaine Debant (M)

INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France.

Miguel Burgos (M)

INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France.

Patrice Hemon (P)

INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France.

Paul Buscaglia (P)

INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France.

Tinhinane Fali (T)

INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France.

Sarra Melayah (S)

INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France.
Laboratory of Immunology and Immunotherapy, CHRU Brest Morvan, Brest, France.

Nelig Le Goux (N)

INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France.

Christophe Vandier (C)

INSERM U1069, N2C, 37032, University of Tours, Tours, France.
IC-CGO network from "Canceropole Grand Ouest", Brest, France.

Marie Potier-Cartereau (M)

INSERM U1069, N2C, 37032, University of Tours, Tours, France.
IC-CGO network from "Canceropole Grand Ouest", Brest, France.

Jacques-Olivier Pers (JO)

INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France.

Adrian Tempescul (A)

INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France.
Department of Haematology, CHRU Brest Morvan, Brest, France.

Christian Berthou (C)

INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France.
Department of Haematology, CHRU Brest Morvan, Brest, France.

Cristina Bagacean (C)

INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France.
Laboratory of Immunology and Immunotherapy, CHRU Brest Morvan, Brest, France.
Department of Haematology, CHRU Brest Morvan, Brest, France.

Olivier Mignen (O)

INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France.
IC-CGO network from "Canceropole Grand Ouest", Brest, France.

Yves Renaudineau (Y)

INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France. yves.renaudineau@univ-brest.fr.
IC-CGO network from "Canceropole Grand Ouest", Brest, France. yves.renaudineau@univ-brest.fr.
Laboratory of Immunology and Immunotherapy, CHRU Brest Morvan, Brest, France. yves.renaudineau@univ-brest.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH